SomaLogic grows sales by 45% in second quarter
BOULDER — SomaLogic Inc. (Nasdaq: SLGC) grew its year-over-year sales by 45% in the second quarter but losses also ticked up in that period.
Revenue for the three months ended June 30, 2023 were $20.5 million, up from $14.1 million in the second quarter of 2022.
SomaLogic’s net loss for the quarter was $24.8 million, up from a loss of $23.0 million in the second quarter of 2022.
“Our second quarter results are in line with our expectations despite navigating operational changes and a dynamic macroeconomic backdrop. While our progress this quarter in both core assay services and distributed kits is encouraging, there…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
